Patent intelligence · US
US 10500284
Pharmaceutical formulation
Pharmaceutical formulation
Patent details — US 10500284
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2019
- Expiration
- Dec 5, 2039
- Applicant
- Semnur Pharmaceuticals, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K31/573, A61K31/661, A61K45/06
Quick answer
US 10500284 (Pharmaceutical formulation) is held by Semnur Pharmaceuticals, Inc.. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Semnur Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/573, A61K31/661, A61K45/06, A61K47/02, A61K47/36
More from Semnur Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12285485
Methods of treating pain
granted -
US 12016867
Methods of treating inflammation and/or pain
granted -
US 11364251
Pharmaceutical formulation
granted -
US 11020485
Pharmaceutical formulation
granted -
US 10744144
Pharmaceutical formulation
granted -
US 10117938
Pharmaceutical formulation
granted -
US 9833460
Pharmaceutical formulation
granted
Frequently asked questions
What is US patent 10500284?
US 10500284 (Pharmaceutical formulation) is held by Semnur Pharmaceuticals, Inc.. Status: granted. Granted Dec 10, 2019. Expires Dec 5, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10500284?
Semnur Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 10500284 expire?
Our index shows an expiration date of Dec 5, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.